Mylan CEO says company failed to properly heed concern over EpiPen prices

The chief executive of Mylan plans to defend the price of EpiPens before Congress on Wednesday, but will acknowledge that the drug maker should have foreseen consumer concern over rising costs, according to an advance copy of her remarks.

“Looking back, I wish we had better anticipated the magnitude and acceleration of the rising financial issues for a growing minority of patients who may have ended up paying the [list price] or more,” Heather Bresch plans to say. “We never intended this.”

Bresch is scheduled to testify before the House Committee on Oversight and Government Reform amid a public outcry over the price of EpiPens and congressional scrutiny.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In